Johnson & Johnson Ordered to Pay Billion-Dollar Penalty for Risperdal

Friday, April 13, 2012
Johnson & Johnson must pay a $1.1 billion judgment after an Arkansas jury found the company guilty of misleading doctors and patients about the antipsychotic drug Risperdal.
 
The company was accused of defrauding Medicaid by not properly disclosing Risperdal’s risks and deceptively marketing it as safer and more effective than similar medicines. Johnson & Johnson also marketed the drug towards children and seniors with various problems, doing so without the approval of the Food and Drug Administration and, indeed, after being warned not to do so. The FDA approved Risperdal only for treatment of schizophrenia, bipolar disorder, and irritability associated with autistic disorder in children and adolescents. Doctors, however, can prescribe it for other conditions, which they were encouraged to do by misleading sales letters from Johnson & Johnson.
 
The penalty is the third and largest so far handed down by a state justice system against the company for the way it sold Risperdal. Previous penalties were issued in Louisiana and South Carolina and the company settled with Texas in January. So far 11 states have sued J&J over Risperdal violations.
 
At its peak in 2007, the drug made $4.5 billion in sales for Johnson & Johnson. The company’s net income last year was $9.7 billion based on $65 billion of revenue. Because no criminal charges have been filed against company executives, it would not be surprising if J&J and other pharmaceutical continued to pursue similar deceptive practices, factoring possible fines, penalties and legal fees into their financial plans.
-David Wallechinsky, Noel Brinkerhoff
 
To Learn More:
J&J Must Pay $1.1 Billion Penalty in Arkansas Risperdal Case (by Eric Francis, Jef Feeley and David Voreacos, Bloomberg)
Arkansas Judge Fines J&J $1.1B in Risperdal Case (by Chuck Bartels, Associated Press)
VA Awards New Contract for Useless Drug (by David Wallechinsky, AllGov)

VA Spent $717 Million for Useless Post-Traumatic Stress Drug (by David Wallechinsky, AllGov) 

Comments

dom 1 year ago
i met a shrink at the va 3 months ago never met her before alot of turn over have been getting meds for ptsd she decided risrerdal was the way to go saying not depression but go this route this after ten minutes after meeting her.i read side effects decided i will not take this.i have a meeting tommorow and wil let them know i am not happy about being given these meds.
Daniel Haszard 2 years ago
risperdal reproached. same saga here as eli lilly zyprexa. johnson and johnson is a trusted brand we associate with babies. risperdal,zyprexa,as well as the other atypical antipsychotics, are being prescribed for children, even though this is an unapproved, off-label use. an estimated 2.5 million children are now taking atypical antipsychotics. over half are being given them for attention deficit hyperactivity disorder,many of these foster children. weight gain, increases in triglyceride levels and associated risks for (life-long) diabetes and cardiovascular disease. eli lilly made $65 billion on zyprexa! was called,"the most successful drug in the history of neuroscience". fmi zyprexa-victims(dot)com *tell the truth don't be afraid* daniel haszard

Leave a comment

captcha